tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Silvan Tuerkcan, 282 are a BUY (98.26%), 5 are a HOLD (1.74%).
Analyst Silvan Tuerkcan, currently employed at JMP, carries an average stock price target met ratio of 37.79% that have a potential upside of 55.85% achieved within 121 days.
Silvan Tuerkcan’s has documented 545 price targets and ratings displayed on 32 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NUVB, Nuvation Bio at 16-Sep-2026.
Analyst best performing recommendations are on NTLA (INTELLIA THERAPEUTICS).
The best stock recommendation documented was for NTLA (INTELLIA THERAPEUTICS) at 6/28/2021. The price target of $160 was fulfilled within 2 days with a profit of $26.57 (19.91%) receiving and performance score of 99.57.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 29-Jul-2025
$51
$-11.23 (-18.05%)
$46
11 days ago
(09-Oct-2026)
6/9 (66.67%)
$-8.86 (-14.80%)
108
Hold Since 19-Aug-2026
$54
$-8.23 (-13.23%)
$56
2 months 1 days ago
(19-Aug-2026)
9/9 (100%)
$-0.39 (-0.72%)
137
Hold Since 27-Feb-2018
$51
$-11.23 (-18.05%)
$47
2 months 14 days ago
(06-Aug-2026)
24/25 (96%)
$-1.2 (-2.30%)
337
Hold Since 07-Jul-2026
$52
$-10.23 (-16.44%)
$56
2 months 14 days ago
(06-Aug-2026)
13/13 (100%)
$-0.2 (-0.38%)
110
Hold Since 20-Jan-2026
$53
$-9.23 (-14.83%)
$50
2 months 27 days ago
(23-Jul-2026)
9/9 (100%)
$-2.65 (-4.76%)
117
Which stock is Silvan Tuerkcan most bullish on?
Which stock is Silvan Tuerkcan most reserved on?
What Year was the first public recommendation made by Silvan Tuerkcan?
